These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
160 related items for PubMed ID: 9472696
1. Antisense RNA-mediated reduction of p53 induces malignant phenotype in nontumorigenic rat urothelial cells. Okamoto M, Hattori K, Fujimoto K, Tanaka Y, Gloosby CL, Oyasu R. Carcinogenesis; 1998 Jan; 19(1):73-9. PubMed ID: 9472696 [Abstract] [Full Text] [Related]
2. WAF1/p21 regulates proliferation, but does not mediate p53-dependent apoptosis in urothelial carcinoma cell lines. Makri D, Schulz WA, Grimm M, Clasen S, Bojar H, Schmitz-Dräger BJ. Int J Oncol; 1998 Mar; 12(3):621-8. PubMed ID: 9472102 [Abstract] [Full Text] [Related]
3. Retinoblastoma protein-initiated cellular growth arrest overcomes the ability of cotransfected wild-type p53 to induce apoptosis. Shinohara H, Zhou J, Yoshikawa K, Yazumi S, Ko K, Yamaoka Y, Mizukami T, Yoshida T, Akinaga S, Tamaoki T, Motoda H, Benedict WF, Takahashi R. Br J Cancer; 2000 Oct; 83(8):1039-46. PubMed ID: 10993652 [Abstract] [Full Text] [Related]
4. p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis. Gao J, Huang HY, Pak J, Cheng J, Zhang ZT, Shapiro E, Pellicer A, Sun TT, Wu XR. Oncogene; 2004 Jan 22; 23(3):687-96. PubMed ID: 14737103 [Abstract] [Full Text] [Related]
5. Effect of transfected interleukin-6 in non-tumorigenic and tumorigenic rat urothelial cell lines. Okamoto M, Oyasu R. Int J Cancer; 1996 Nov 27; 68(5):616-21. PubMed ID: 8938144 [Abstract] [Full Text] [Related]
6. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression. Quentin T, Henke C, Korabiowska M, Schlott T, Zimmerman B, Kunze E. Anticancer Res; 2004 Nov 27; 24(2B):1011-23. PubMed ID: 15161057 [Abstract] [Full Text] [Related]
7. In vitro and in vivo acceleration of the neoplastic phenotype of a low-tumorigenicity rat bladder carcinoma cell line by transfected transforming growth factor-alpha. Kawamata H, Kameyama S, Oyasu R. Mol Carcinog; 1994 Apr 27; 9(4):210-9. PubMed ID: 8148054 [Abstract] [Full Text] [Related]
8. Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line. Okamoto M, Oyasu R. Cell Growth Differ; 1997 Aug 27; 8(8):921-6. PubMed ID: 9269901 [Abstract] [Full Text] [Related]
9. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells. Hu G, Liu W, Hanania EG, Fu S, Wang T, Deisseroth AB. Cancer Gene Ther; 1995 Mar 27; 2(1):19-32. PubMed ID: 7621252 [Abstract] [Full Text] [Related]
10. Tumorigenic conversion of a rat urothelial cell line by human polymorphonuclear leukocytes activated by lipopolysaccharide. Tamatani T, Turk P, Weitzman S, Oyasu R. Jpn J Cancer Res; 1999 Aug 27; 90(8):829-36. PubMed ID: 10543254 [Abstract] [Full Text] [Related]
11. FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma. Zhou H, He F, Mendelsohn CL, Tang MS, Huang C, Wu XR. Sci Rep; 2016 May 09; 6():25596. PubMed ID: 27157475 [Abstract] [Full Text] [Related]
12. Transformation in vitro of a nontumorigenic rat urothelial cell line by hydrogen peroxide. Okamoto M, Kawai K, Reznikoff CA, Oyasu R. Cancer Res; 1996 Oct 15; 56(20):4649-53. PubMed ID: 8840979 [Abstract] [Full Text] [Related]
14. Tumorigenic conversion of a non-tumorigenic rat urothelial cell line by overexpression of H2O2-generating peroxisomal fatty acyl-CoA oxidase. Okamoto M, Reddy JK, Oyasu R. Int J Cancer; 1997 Mar 17; 70(6):716-21. PubMed ID: 9096654 [Abstract] [Full Text] [Related]
15. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas. Goto K, Konomoto T, Hayashi K, Kinukawa N, Naito S, Kumazawa J, Tsuneyoshi M. Mod Pathol; 1997 May 17; 10(5):428-37. PubMed ID: 9160306 [Abstract] [Full Text] [Related]
16. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers. Sarkar S, Jülicher KP, Burger MS, Della Valle V, Larsen CJ, Yeager TR, Grossman TB, Nickells RW, Protzel C, Jarrard DF, Reznikoff CA. Cancer Res; 2000 Jul 15; 60(14):3862-71. PubMed ID: 10919661 [Abstract] [Full Text] [Related]
17. Adriamycin induced G2/M cell cycle arrest in transitional cell cancer cells with wt p53 and p21(WAF1/CIP1) genes. Bilim V, Kawasaki T, Takahashi K, Tomita Y. J Exp Clin Cancer Res; 2000 Dec 15; 19(4):483-8. PubMed ID: 11277327 [Abstract] [Full Text] [Related]
18. Effect of epidermal growth factor/transforming growth factor alpha and transforming growth factor beta 1 on growth in vitro of rat urinary bladder carcinoma cells. Kawamata H, Azuma M, Kameyama S, Nan L, Oyasu R. Cell Growth Differ; 1992 Nov 15; 3(11):819-25. PubMed ID: 1467309 [Abstract] [Full Text] [Related]
19. Chromosomal imbalances in successive moments of human bladder urothelial carcinoma. Nascimento e Pontes MG, da Silveira SM, Trindade Filho JC, Rogatto SR, Viana de Camargo JL. Urol Oncol; 2013 Aug 15; 31(6):827-35. PubMed ID: 21763161 [Abstract] [Full Text] [Related]
20. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Burfeind P, Chernicky CL, Rininsland F, Ilan J, Ilan J. Proc Natl Acad Sci U S A; 1996 Jul 09; 93(14):7263-8. PubMed ID: 8692980 [Abstract] [Full Text] [Related] Page: [Next] [New Search]